即时询价 ×
* 必填项
请填妥以下表格,您将在一分钟内得到邮件机器人给你的报价。
Inquiry Online
×
* Required Fields.
Please complete the form below and we will contact you shortly.
Bulk Inquiry
×
* Required Fields.
Please complete the form below and we will contact you shortly.
CAS号 | 1204918-72-8 | 货号 | BCP42651 |
关联产品 | 937270-47-8(SB-1317) | ||
中文名 | SB1317 | ||
英文名 | SB1317 | ||
中文别名 | |||
英文别名 | Ex45; Ex-45; EX 45; TG02; TG 02; TG02; SB1317; SB 1317; Zotiraciclib; | ||
SMILES | CN1C/C=C/CCOC2=CC=CC(=C2)C3=NC(=NC=C3)NC4=CC=CC(=C4)C1 | ||
化学名称 | |||
分子式 | C23H24N4O | 分子量 | 372.46 |
纯度 | 98% | 配送 | 惯例下常温包邮 |
产品描述 | SB1317 is a novel small molecule potent CDK/JAK2/FLT3 inhibitor. It dose-dependently inhibits signaling pathways downstream of CDKs, JAK2 and FLT3 in cancer cells with the main targets being CDKs. SB1317 is anti-proliferative in a broad range of tumor cell lines, inducing G1 cell cycle arrest and apoptosis. In vivo, SB1317 exhibits favorable pharmacokinetics after oral dosing in xenograft models and accumulates in tumor tissues, inducing an effective blockade of both CDK and STAT signaling. SB1317 induces tumor regression after oral dosing on both daily and intermittent schedules in a murine model of mutant-FLT3 leukemia (MV4-11) and prolongs survival in a disseminated AML model with wild-type FLT3 and JAK2 (HL-60). SB1317 is active in various models of leukemia and provide a rationale for the ongoing clinical evaluation of TG02 in patients with advanced leukemias. |
相关产品推荐
查看更多 >Tags:SB1317 供应商,SB1317 购买,SB1317 生产,SB1317 批量,SB1317 供应,SB1317 订购,SB1317 采购